The sympathetic nervous system (SNS) and the renin-angiotensin system (RAS) play important roles in regulating renal hemodynamics. Given the complexity of these two systems, a deeper understanding of their interplay may yield valuable insights for developing innovative therapeutic strategies aimed at managing cardiovascular and renal disorders and preserving kidney function. This study investigated the renal hemodynamic responses to Angiotensin-(1–7) (Ang-(1–7)) in intact and chronically denervated male and female rats, with or without Angiotensin II type 1 receptor (AT1R) blockade.
Methods
A total of 54 Wistar rats (26 males, 28 females) underwent right nephrectomy and were assigned to intact or chronic renal denervation (CRDN) groups. Each group received either saline or losartan, followed by graded Ang-(1–7) infusions. Mean arterial pressure (MAP), renal perfusion pressure (RPP), renal blood flow (RBF), and renal vascular resistance (RVR) were recorded. RPP was controlled during Ang-(1–7) infusion, and female rats were studied during the diestrus phase.
Results
At baseline, a significant increase in RVR and a decrease in RBF were observed in both male and female CRDN groups. The compensatory kidney hypertrophy was detected in denervated rats. Changes in renal hemodynamic parameters, including RBF and RVR, in saline- or losartan-treated groups of both sexes showed no significant differences between intact and CRDN groups before Ang-(1–7) administration. However, Ang-(1–7) infusion elevated RBF (Pdose = 0.03) and attenuated RVR (Pdose = 0.027) in male rats treated with saline or losartan (RBF; Pdose = 0.001, RVR; Pdose < 0.001), but this response was only significantly different between intact and CRDN male rats treated with losartan (RBF; Pgroup = 0.01, RVR; Pgroup = 0.002). Such findings were not observed in female rats. Serum nitrite levels were significantly reduced (Pgroup = 0.04) in male CRDN rats treated with losartan compared to the corresponding intact group.
Conclusion
AT1R blockade unmasks a Mas receptor (MasR)-dependent vasodilatory pathway for Ang-(1–7) that is neurally gated in males but estrogen-dependent in females. These findings highlight a sex-dependent neuro-hormonal mechanism that may underlie variable outcomes of renal denervation therapies.
TsioufisCPapademetriouVDimitriadisK, et al.Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. Int J Cardiol2013; 168: 987–992.
2.
BlankestijnPJLondonGFliserD, et al.Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems. Kidney Int Suppl2011; 1: 13–16.
3.
SalmanIMSattarMAAbdullahNA, et al.Renal functional & haemodynamic changes following acute unilateral renal denervation in sprague dawley rats. Indian J Med Res2010; 131: 76–82.
4.
KannanAMedinaRINagajothiN, et al.Renal sympathetic nervous system and the effects of denervation on renal arteries. World J Cardiol2014; 6: 814.
5.
MahfoudFBöhmMSchmiederR, et al.Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J2019; 40: 3474–3482.
6.
NammasWKoistinenJPaanaT, et al.Renal sympathetic denervation for treatment of patients with heart failure: summary of the available evidence. Ann Med2017; 49: 384–395.
7.
AziziMSchmiederREMahfoudF, et al.Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet2018; 391: 2335–2345.
8.
FenglerKRommelK-PBlazekS, et al.A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation2019; 139: 590–600.
9.
KrumHSchlaichMPSobotkaPA, et al.Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the symplicity HTN-1 study. Lancet2014; 383: 622–629.
10.
SchlaichMPHeringDSobotkaPA, et al.Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep2012; 14: 247–253.
11.
FeyzLvan den BergSZietseR, et al.Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst2020; 21: 1470320320943095.
12.
LiXCZhangJZhuoJL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res2017; 125: 21–38.
13.
de Souza-NetoFPCarvalho SantuchiMde Morais e SilvaM, et al.Angiotensin-(1–7) and alamandine on experimental models of hypertension and atherosclerosis. Curr Hypertens Rep2018; 20: 1–15.
14.
KoboriHNangakuMNavarLG, et al.The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev2007; 59: 251–287.
15.
PatelVBZhongJ-CGrantMB, et al.Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ Res2016; 118: 1313–1326.
16.
De GasparoMCattKInagamiT, et al.International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev2000; 52: 415–472.
17.
NavarLGHarrison-BernardLMNishiyamaA, et al.Regulation of intrarenal angiotensin II in hypertension. Hypertension2002; 39: 316–322.
18.
SparksMACrowleySDGurleySB, et al.Classical renin-angiotensin system in kidney physiology. Compr Physiol2014; 4: 1201.
19.
RüsterCWolfG. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol2006; 17: 2985–2991.
20.
SiragyHM. AT1 and AT2 receptor in the kidney: role in health and disease. Semin Nephrol2004; 24: 93–100.
21.
ChaiWWangWLiuJ, et al.Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension2010; 55: 523–530.
22.
YuX-JMiaoY-WLiH-B, et al.Blockade of endogenous angiotensin-(1–7) in hypothalamic paraventricular nucleus attenuates high salt-induced sympathoexcitation and hypertension. Neurosci Bull2019; 35: 47–56.
23.
KongYZhaoXQiuM, et al.Tubular Mas receptor mediates lipid-induced kidney injury. Cell Death Dis2021; 12: 110.
24.
FyhrquistFSaijonmaaO. Renin-angiotensin system revisited. J Intern Med2008; 264: 224–236.
25.
BaderM. ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflügers Arch Eur J Physiol2013; 465: 79–85.
26.
FerrarioCChappellM. What’s new in the renin-angiotensin system? Novel angiotensin peptides. Cell Mol Life Sci2004; 61: 2720–2727.
27.
SantosRASSampaioWOAlzamoraAC, et al.The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiol Rev2017; 98: 505–553.
28.
SampaioWOSouza dos SantosRAFaria-SilvaR, et al.Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension2007; 49: 185–192.
29.
ChoopaniSNematbakhshM. Sex difference in MasR expression and functions in the renal system. J Renin Angiotensin Aldosterone Syst2022; 2022: 1327839.
30.
RabeloLAAleninaNBaderM. ACE2–angiotensin-(1–7)–Mas Axis and oxidative stress in cardiovascular disease. Hypertens Res2011; 34: 154–160.
31.
SantosELReisRISilvaRG, et al.Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene. Regul Pept2007; 141: 159–167.
32.
PeiróCVallejoSGembardtF, et al.Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens2007; 25: 2421–2425.
33.
SaberiSDehghaniANematbakhshM. Role of Mas receptor in renal blood flow response to angiotensin-(1–7) in ovariectomized estradiol treated rats. Res Pharm Sci2016; 11: 65–72.
34.
PinheiroSVBSimões e SilvaAC. Angiotensin converting enzyme 2, Angiotensin-(1–7), and receptor MAS axis in the kidney. Int J Hypertens2012; 2012: 414128.
35.
Simões e SilvaASilveiraKFerreiraA, et al.ACE2, Angiotensin-(1-7) and M as receptor axis in inflammation and fibrosis. Br J Pharmacol2013; 169: 477–492.
36.
PotthoffSAFählingMClasenT, et al.Angiotensin-(1–7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E–deficient mice. Hypertension2014; 63: 265–272.
37.
BürgelováMKramerHJTeplanV, et al.Intrarenal infusion of angiotensin-(1–7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res2002; 25: 202–210.
38.
NematbakhshMSafariT. Role of Mas receptor in renal blood flow response to angiotensin (1–7) in male and female rats. Gen Physiol Biophys2014; 33: 365–372.
39.
NematbakhshMMansouriA. Renal vascular response to angiotensin 1–7 in rats: the role of Mas receptor. Res Pharm Sci2018; 13: 177.
40.
HilliardLMSampsonAKBrownRD, et al.The “his and hers” of the renin-angiotensin system. Curr Hypertens Rep2013; 15: 71–79.
41.
OttCJankaRSchmidA, et al.Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol2013; 8: 1195–1201.
42.
KoppUCDiBonaGF. Neural control of renal function. Reflex control of the circulation. Boca Raton, FL, USA: CRC Press, 2020, pp. 493–528.
43.
LiaoWWuJ. The ACE2/Ang (1–7)/MasR axis as an emerging target for antihypertensive peptides. Crit Rev Food Sci Nutr2021; 61: 2572–2586.
44.
Muñoz AbellánCMangold-GehringSMicusS, et al.A novel model of chronic kidney disease in rats: dietary adenine in combination with unilateral nephrectomy. Kidney Dis (Basel)2019; 5: 135–143.
45.
CaiX-NWangC-YCaiY, et al.Effects of renal denervation on blood-pressure response to hemorrhagic shock in spontaneously hypertensive rats. Chin J Traumatol2018; 21: 293–300.
46.
CoraMCKooistraLTravlosG. Vaginal cytology of the laboratory rat and mouse: review and criteria for the staging of the estrous cycle using stained vaginal smears. Toxicol Pathol2015; 43: 776–793.
47.
MarcondesFBianchiFTannoA. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol2002; 62: 609–614.
48.
AjayiAFAkhigbeRE. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. Fertil Res Pract2020; 6: 1–15.
49.
DimitriadouVAubineauPTaxiJ, et al.Ultrastructural changes in the cerebral artery wall induced by long-term sympathetic denervation. J Vasc Res1988; 25: 122–143.
50.
FronekK. Trophic effect of the sympathetic nervous system on vascular smooth muscle. Ann Biomed Eng1983; 11: 607–615.
51.
BrancoDTeixeiraAAAzevedoI, et al.Structural and functional alterations caused at the extraneuronal level by sympathetic denervation of blood vessels. Naunyn-Schmiedeberg's Arch Pharmacol1984; 326: 302–312.
52.
DabHKacemKHachaniR, et al.Physiological regulation of extracellular matrix collagen and elastin in the arterial wall of rats by noradrenergic tone and angiotensin II. J Renin Angiotensin Aldosterone Syst2012; 13: 19–28.
53.
LacolleyPGlaserEChallandeP, et al.Structural changes and in situ aortic pressure-diameter relationship in long-term chemical-sympathectomized rats. Am J Physiol Heart Circ Physiol1995; 269: H407–HH16.
54.
FigueroaXFDulingBR. Gap junctions in the control of vascular function. Antioxid Redox Signaling2009; 11: 251–266.
55.
SlovutDPMehtaSHDorranceAM, et al.Increased vascular sensitivity and connexin43 expression after sympathetic denervation. Cardiovasc Res2004; 62: 388–396.
56.
WestfallDPMillecchiaLLLeeTJ-F, et al.Effects of denervation and reserpine on nexuses in the rat vas deferens. Eur J Pharmacol1977; 41: 239–242.
57.
ColucciWSGimbrone JrMAAlexanderRW. Regulation of the postsynaptic alpha-adrenergic receptor in rat mesenteric artery. Effects of chemical sympathectomy and epinephrine treatment. Circ Res1981; 48: 104–111.
58.
BentzerPNielsenNArnerM, et al.Supersensitivity in rat micro-arteries after short-term denervation. Acta Physiol Scand1997; 161: 125–133.
59.
van LoonLMRongenGAvan der HoevenJG, et al.Β-blockade attenuates renal blood flow in experimental endotoxic shock by reducing perfusion pressure. Physiol Rep2019; 7: e14301.
60.
LannemyrLBragadottirGKrumbholzV, et al.Effects of cardiopulmonary bypass on renal perfusion, filtration, and oxygenation in patients undergoing cardiac surgery. Anesthesiology2017; 126: 205–213.
61.
MitrmoonpitakCChulasugandhaPKhowO, et al.Effects of phospholipase A2 and metalloprotease fractions of Russell's viper venom on cytokines and renal hemodynamics in dogs. Toxicon2013; 61: 47–53.
62.
WegnerJ. Hemodilution: physiology and pathophysiology. Minimized cardiopulmonary bypass techniques and technologies. Cambridge, UK: Woodhead Publishing, 2012, pp. 62–85.
63.
TranPNTKusirisinPKaewdoungtienP, et al.Higher blood pressure versus normotension targets to prevent acute kidney injury: a systematic review and meta-regression of randomized controlled trials. Crit Care2022; 26: 364.
64.
BeloncleFPiquilloudLAsfarP. Renal blood flow and perfusion pressure. Crit Care Nephrol2019: 106–9.e2.
65.
Harrison-BernardLM. The renal renin-angiotensin system. Adv Physiol Educ2009; 33: 270–274.
66.
SataYHeadGADentonK, et al.Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med (Lausanne)2018; 5: 82.
67.
DorringtonKPanditJ. The obligatory role of the kidney in long-term arterial blood pressure control: extending Guyton’s model of the circulation. Anaesthesia2009; 64: 1218–1228.
68.
MesserliFHBangaloreS. Renal denervation for resistant hypertension. N Engl J Med2014; 370: 1454–1457.
69.
WangMHanWZhangM, et al.Long-term renal sympathetic denervation ameliorates renal fibrosis and delays the onset of hypertension in spontaneously hypertensive rats. Am J Transl Res2018; 10: 4042.
70.
WeiSLiDZhangY, et al.Perivascular radiofrequency renal denervation lowers blood pressure and ameliorates cardiorenal fibrosis in spontaneously hypertensive rats. PLoS One2017; 12: e0176888.
71.
CalzavaccaPMayCNBellomoR. Glomerular haemodynamics, the renal sympathetic nervous system and sepsis-induced acute kidney injury. Nephrol Dial Transplant2014; 29: 2178–2184.
72.
HartECCharkoudianNWallinBG, et al.Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension2009; 53: 571–576.
73.
Hinojosa-LabordeCChapaILangeD, et al.Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol1999; 26: 122–126.
74.
SalehTMConnellBJ. 17β-Estradiol Modulates baroreflex sensitivity and autonomic tone of female rats. J Auton Nerv Syst2000; 80: 148–161.
75.
ChristouDDJonesPPJordanJ, et al.Women have lower tonic autonomic support of arterial blood pressure and less effective baroreflex buffering than men. Circulation2005; 111: 494–498.
76.
JoynerMJBarnesJNHartEC, et al.Neural control of the circulation: how sex and age differences interact in humans. Compr Physiol2015; 5: 193–215.
77.
SandbergKUmansJGGroupGCCW. Recommendations concerning the new US national institutes of health initiative to balance the sex of cells and animals in preclinical research. FASEB J2015; 29: 1646.
78.
SullivanJC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Reg Integr Compar Physiol2008; 294: R1220–R12R6.
79.
NwiaSMLeiteAPOLiXC, et al.Sex differences in the renin-angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and kidney diseases. Front Cardiovasc Med2023; 10: 1198090.
80.
LeeSHLeeYHJungSW, et al.Sex-related differences in the intratubular renin-angiotensin system in two-kidney, one-clip hypertensive rats. Am J Physiol Renal Physiol2019; 317: F670–FF82.
81.
e SilvaASPinheiroSVPereiraRM, et al.The therapeutic potential of angiotensin-(1–7) as a novel renin-angiotensin system mediator. Mini Rev Med Chem2006; 6: 603.
82.
ChappellMCModrallJGDizDI, et al.Novel aspects of the renal renin-angiotensin system: angiotensin-(1–7), ACE2 and blood pressure regulation. Contrib Nephrol2004; 143: 77–89.
83.
van der WoudenEAOchodnickýPvan DokkumRP, et al.The role of angiotensin (1–7) in renal vasculature of the rat. J Hypertens2006; 24: 1971–1978.
84.
StegbauerJOberhauserVVonendO, et al.Angiotensin-(1–7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc Res2004; 61: 352–359.
85.
Simões-e-SilvaABarachoNPassaglioK, et al.Renal actions of angiotensin-(1–7). Braz J Med Biol Res1997; 30: 503–513.
86.
KuczeriszkaMDobrowolskiLWalkowskaA, et al.Role of Ang1-7 in renal haemodynamics and excretion in streptozotocin diabetic rats. Clin Exp Pharmacol Physiol2022; 49: 432–441.
87.
BarryEFAbdullaMHO'NeillJ, et al.Effects of intrarenal angiotensin 1–7 infusion on renal haemodynamic and excretory function in anaesthetised two-kidney one-clip and deoxycorticosterone acetate-salt hypertensive rats. Exp Physiol2023; 108: 268–279.
88.
SouzaÁPSobrinhoDBAlmeidaJF, et al.Angiotensin II type 1 receptor blockade restores angiotensin-(1–7)-induced coronary vasodilation in hypertrophic rat hearts. Clin Sci2013; 125: 449–459.
89.
RenYGarvinJLCarreteroOA. Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension2002; 39: 799–802.
90.
van RodijnenWFvan LambalgenTAvan WijheMH, et al.Renal microvascular actions of angiotensin II fragments. Am J Physiol Renal Physiol2002; 283: F86–F92.
91.
HandaRKFerrarioCMStrandhoyJW. Renal actions of angiotensin-(1–7): in vivo and in vitro studies. Am J Physiol Renal Physiol1996; 270: F141–F1F7.
92.
UedaSMasumori-MaemotoSAshinoK, et al.Angiotensin-(1–7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension2000; 35: 998–1001.
93.
KuczeriszkaMKompanowska-JezierskaESadowskiJ, et al.Modulating role of Ang-(1–7) in control of blood pressure and renal function in AngII-infused hypertensive rats. Am J Hypertens2018; 31: 504–511.
94.
SantosRFerreiraAJVerano-BragaT, et al.Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system. J Endocrinol2013; 216: R1–R17.
95.
BrosnihanKBLiPFerrarioCM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension1996; 27: 523–528.
96.
PörstiIBaraATBusseR, et al.Release of nitric oxide by angiotensin-(1–7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J of Pharmacology1994; 1994111: 652–654.
SantosRAe SilvaACSMaricC, et al.Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA2003; 100: 8258–8263.
99.
SavergniniSQOBeimanMLautnerRQ, et al.Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension2010; 56: 112–120.
100.
OseiSYAhimaRSMinkesRK, et al.Differential responses to angiotensin-(1–7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol1993; 234: 35–42.
101.
MachadoRFerreiraMBeloA, et al.Vasodilator effect of angiotensin-(1–7) in mature and sponge-induced neovasculature. Regul Pept2002; 107: 105–113.
102.
OliveiraMAFortesZBSantosRA, et al.Synergistic effect of angiotensin-(1–7) on bradykinin arteriolar dilation in vivo. Peptides1999; 20: 1195–1201.
103.
FernandesLFortesZBNigroD, et al.Potentiation of bradykinin by angiotensin-(1–7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension2001; 37: 703–709.
104.
AlmeidaAFrabregasBMadureiraM, et al.Angiotensin-(1–7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res2000; 33: 709–713.
105.
De MouraRSResendeAEmilianoA, et al.The role of bradykinin, AT2 and angiotensin 1–7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol2004; 141: 860–866.
106.
SampaioWONascimentoAASantosRA. Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats. Am J Physiol Heart Circ Physiol2003; 284: H1985–H1H94.
107.
SinghRRMcArdleZMBoothLC, et al.Increase in bioavailability of nitric oxide after renal denervation improves kidney function in sheep with hypertensive kidney disease. Hypertension2021; 77: 1299–1310.
108.
KharazmiFPourshanazariA-ANematbakhshM. The role of the AT1 receptor antagonist on renal hemodynamic responses to angiotensin 1–7 in acute sympathectomized male and female rats. Physiol Pharmacol2024; 28: 190–205.
109.
HellerJKramerHMalýJ, et al.Effect of intrarenal infusion of angiotensin–(1–7) in the dog. Kidney Blood Press Res2000; 23: 89–94.
DilauroMBurnsKD. Angiotensin-(1–7) and its effects in the kidney. Scientific World J2009; 9: 522–535.
112.
VallonVRichterKHeyneN, et al.Effect of intratubular application of angiotensin 1–7 on nephron function. Kidney Blood Press Res2004; 20: 233–239.
113.
MagaldiAJCesarKRde AraújoM, et al.Angiotensin-(1–7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V 2 receptors. Pflügers Arch2003; 447: 223–230.
114.
OuditGYKassiriZPatelMP, et al.Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res2007; 75: 29–39.
115.
SaberiSDehghaniANematbakhshM. Angiotensin 1–7 administration increases renal blood flow in the absence of bradykinin B2 receptor in ovariectomized estradiol treated rats: the role of mas receptor. Acta Med Iran2019; 57: 103–109.
116.
YokotaKKishidaMOguraT, et al.Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. Hypertens Res2003; 26: 265–272.
117.
SiragyHMde GasparoMEl-KershM, et al.Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension2001; 38: 183–186.
118.
WaltersPEGaspariTAWiddopRE. Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension2005; 45: 960–966.
119.
CostaMALopez VerrilliMAGomezKA, et al.Angiotensin-(1–7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol2010; 299: H1205–H1H11.
120.
HilgersKFMannJF. ACE Inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol2002; 13: 1100–1108.
121.
UedaSMasumori-MaemotoSWadaA, et al.Angiotensin (1–7) potentiates bradykinin-induced vasodilatation in man. J Hypertens2001; 19: 2001–2009.
122.
SafariTShahrakiMRMiriS, et al.The effect of angiotensin 1–7 and losartan on renal ischemic/reperfusion injury in male rats. Res Pharm Sci2019; 14: 441.
123.
CollisterJPHendelMD. The role of Ang (1–7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst2003; 4: 176–179.
124.
YousifMHBenterIFDizDI, et al.Angiotensin-(1–7)-dependent vasorelaxation of the renal artery exhibits unique angiotensin and bradykinin receptor selectivity. Peptides2017; 90: 10–16.
125.
NevesLAAverillDBChappellMC, et al.Characterization of angiotensin-(1–7) receptor subtype in mesenteric arteries. Peptides2003; 24: 455–462.
126.
VallonVHeyneNRichterK, et al.[7-D-ALA]-angiotensin 1–7 blocks renal actions of angiotensin 1–7 in the anesthetized rat. J Cardiovasc Pharmacol1998; 32: 164–167.
127.
BohlenderJMNussbergerJBirkhäuserF, et al.Resetting of renal tissular renin–angiotensin and bradykinin–kallikrein systems after unilateral kidney denervation in rats. Histochem Cell Biol2017; 147: 585–593.
128.
SiragyHMInagamiTIchikiT, et al.Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA1999; 96: 6506–6510.
129.
SpornitzUSocinCDravidA. Estrous stage determination in rats by means of scanning electron microscopic images of uterine surface epithelium. Anat Record1999; 254: 116–126.
130.
Costa-FragaFPGoncalvesGKSouza-NetoFP, et al.Age-related changes in vascular responses to angiotensin-(1–7) in female mice. J Renin Angiotensin Aldosterone Syst2018; 19: 1470320318789332.
131.
MenezesLAEndlichPWLimaDSS, et al.Effects of hormone replacement treatment with estrogen and progestins on the vascular renin–angiotensin system of ovariectomized rats. Int J Mol Sci2025; 26: 4930.
132.
NevesLAAverillDBFerrarioCM, et al.Vascular responses to angiotensin-(1–7) during the estrous cycle. Endocrine2004; 24: 161–165.
133.
NevesLAWilliamsAFAverillDB, et al.Pregnancy enhances the angiotensin (Ang)-(1–7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1–7). Endocrinology2003; 144: 3338–3343.
134.
ArmandoIJezovaMJuorioAV, et al.Estrogen upregulates renal angiotensin II AT2receptors. Am J Physiol Renal Physiol2002; 283: F934–FF43.
135.
Silva-AntonialliMMTostesRCFernandesL, et al.A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res2004; 62: 587–593.
136.
SampsonAKMoritzKMDentonKM. Postnatal ontogeny of angiotensin receptors and ACE2 in male and female rats. Gend Med2012; 9: 21–32.
137.
SobrinoAVallejoSNovellaS, et al.Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation. Biochem Pharmacol2017; 129: 67–72.
138.
WongPCBernardRTimmermansPB. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension1992; 19: 663–667.
139.
McArdleZSchreuderMFMoritzKM, et al.Physiology and pathophysiology of compensatory adaptations of a solitary functioning kidney. Front Physiol2020; 11: 725.
140.
Rojas-CanalesDMLiJYMakueiL, et al.Compensatory renal hypertrophy following nephrectomy: when and how?Nephrology2019; 24: 1225–1232.
141.
HeumannPKoenenAZavaritskayaO, et al.Sympathetic denervation facilitates L-type Ca2+channel activation in renal but not in mesenteric resistance arteries. J Hypertens2016; 34: 692–703.
142.
LiuH. Nav channels in cancers: nonclassical roles. Glob J Cancer Ther2020; 6: 5.
143.
PassagliaPde Lima FaimFBatalhãoME, et al.Central angiotensin-(1–7) attenuates systemic inflammation via activation of sympathetic signaling in endotoxemic rats. Brain Behav Immun2020; 88: 606–618.
144.
LiSHildrethCMRahmanAA, et al.Renal denervation does not affect hypertension or the renin-angiotensin system in a rodent model of juvenile-onset polycystic kidney disease: clinical implications. Sci Rep2021; 11: 14286.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
